Additionally, the results showed that elevated PTX3 expression was associated with reduced survival rates in patients with G4, IDH wild-type, 1p/19q non-codel in patients diagnosed with glioma (Figs. 6I–6K). This evidence concerns the gene PTX3 and central nervous system cancer.